PAUL VANVELDHUISEN was named chief operating officer of The Emmes Corporation. VanVeldhuisen will continue to serve as principal investigator for government and privately funded research projects. VanVeldhuisen joined the company in 1993 and was promoted to vice president in 2006. He is responsible for the scientific aspects of various research studies, including study design and...
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.Â
